Octreotide
Who holds supplier records for Octreotide? 10 organisations hold a current record for Octreotide: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 10 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (5), India (2) and Sweden (1); not recorded for 2.
Most records are filed under another form of this substance: Octreotide Acetate (23 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Octreotide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/octreotide
Reading the evidence
- 10 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in China
5 of the 8 current records with a recorded country list China. Organisation country is not necessarily the manufacturing site.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Octreotide expires 29 Dec 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (10)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Octreotide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- AURO PEPTIDES LTDCEP
- BACHEM AGCEP Company GMP cert on record
- ChinaCEP
- Hybio Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on record
- IndiaCEP
- PolyPeptide Laboratories (Sweden) ABSwedenCEP Company GMP cert on record
- Shanghai Soho-Yiming Pharmaceuticals Co., Ltd.ChinaCEP
- IndiaCEP
- ChinaCEP
- ChinaCEP
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (10)
Certificates of Suitability on the EDQM register for Octreotide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| SHANGHAI SOHO-YIMING PHARMACEUTICALS CO., LTD. Shanghai | CN | CEP 2025-235 - Rev 00 Octreotide | Jul 2026 | — |
| MATRIX PHARMACORP PRIVATE LIMITED Sangareddy | IN | CEP 2022-031 - Rev 02 Octreotide | May 2026 | — |
| BACHEM AG Bubendorf | CH | CEP 2020-229 - Rev 02 Octreotide | Feb 2026 | Inspected Aug 2024 Switzerland |
| AURO PEPTIDES LIMITED Kandi Mandal | IN | CEP 2023-017 - Rev 00 Octreotide | Mar 2025 | — |
| SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. Lianyungang | CN | CEP 2022-302 - Rev 01 Octreotide | Mar 2025 | — |
| SHILPA PHARMA LIFESCIENCES LIMITED Raichur | IN | CEP 2024-102 - Rev 00 Octreotide | Nov 2024 | — |
| SUZHOU TIANMA PHARMA GROUP TIANJI BIO-PHARMACEUTICAL CO., LTD Suzhou City | CN | CEP 2023-370 - Rev 00 Octreotide | Nov 2024 | — |
| CHENGDU SHENGNUO BIOPHARM CO., LTD. Chengdu City | CN | R0-CEP 2021-365 - Rev 00 Octreotide | Oct 2022 | — |
| PolyPeptide Laboratories (Sweden) AB Limhamn | SE | R0-CEP 2021-279 - Rev 00 Octreotide | Apr 2022 | — |
| HYBIO PHARMACEUTICAL CO., LTD. Shenzhen | CN | R0-CEP 2021-253 - Rev 00 Octreotide | Mar 2022 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (1)
Organisations whose Type II DMFs for Octreotide are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- United States · Inactive DMF 21704 · filed Jun 2008
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (46 listed products contain Octreotide). The latest listed patent expires 29 Dec 2041. The latest listed exclusivity runs to 26 Jun 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Octreotide is a protein active pharmaceutical ingredient (ChEMBL CHEMBL1680).
Chemical identity
- IUPAC name
- (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
- Canonical SMILES
- C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
- InChIKey
- DEQANNDTNATYII-OULOTJBUSA-N
- Synonyms
- Octreotida, Octreotide, SMS 201-995, SMS-201-995, SMS-995, SMS995, Octreotidum, DRG-0115, CHEBI:7726, Compound 201995, Octreotide Acetate Salt, RefChem:59031
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Somatostatin Analog
- Mechanism of action
- Somatostatin Receptor Agonists
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Octreotide?
10 organisations hold an active US FDA Type II Drug Master File or a CEP for Octreotide: AURO PEPTIDES LTD, BACHEM AG, CHENGDU SHENGNUO BIOPHARM CO LTD (China), Hybio Pharmaceutical Co., Ltd. (China), MATRIX PHARMACORP PRIVATE LTD (India), PolyPeptide Laboratories (Sweden) AB (Sweden), Shanghai Soho-Yiming Pharmaceuticals Co., Ltd. (China) and SHILPA PHARMA LIFESCIENCES LTD (India), and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
What do the historical Octreotide records mean?
1 organisation has only inactive Type II DMFs for Octreotide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Octreotide have a European Certificate of Suitability?
Yes. 10 organisations hold a valid CEP for Octreotide on the EDQM register, including SHANGHAI SOHO-YIMING PHARMACEUTICALS CO., LTD. Shanghai (CN), MATRIX PHARMACORP PRIVATE LIMITED Sangareddy (IN), BACHEM AG Bubendorf (CH), AURO PEPTIDES LIMITED Kandi Mandal (IN), SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. Lianyungang (CN) and SHILPA PHARMA LIFESCIENCES LIMITED Raichur (IN) and 4 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Octreotide?
Yes. The latest patent listed for an approved US product containing Octreotide expires 29 Dec 2041, across 46 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Octreotide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Octreotide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.